What is Decree No. 101 / 2022 Coll.?

Decree No. 101 / 2022 Coll., on the epidemiological vigilance system for COVID-19 disease — Decree on the epidemiological vigilance system for COVID-19.

When it became Decree No. 101 / 2022 Coll. effectiveness?

Decree No. 101 / 2022 Coll. became effective 01.05.2022.

Is Decree No. 101 / 2022 Coll. still valid?

Yes, Decree No. 101 / 2022 Coll. is still valid and effective.

How many times was it Decree No. 101 / 2022 Coll. amended?

Decree No. 101 / 2022 Coll. has 4 time versions of the text.

Decree No. 101 / 2022 Coll. - Decree on the epidemiological vigilance...

101

DECLARATION

of 20 April 2022

on the epidemiological vigilance system for COVID-19 disease

According to Article 108 (1) of the Act No. 258 / 2000 Coll., on the Protection of Public Health and on the Amendment of Certain Related Acts, as amended by Act No. 274 / 2001 Coll., Act No. 274 / 2003 Coll., Act No. 320 / 2002 Coll., Act No. 392 / 2005 Coll., Act No. 222 / 2006 Coll., Act No. 110 / 2007 Coll. and Act No. 267 / 2015 Coll., ("the Act ') to implement Sections 62 (1) and (3) (b) and § 75a (1) and (4) of the Act:

§ 1

(1) This Decree establishes a system of epidemiological vigilance ("surveillance") for COVID-19 disease and provides in Annex 1 to that Decree:

(a) the essential characteristics, the clinical definition and classification of the disease COVID-19,

(b) procedures for the epidemiological investigation of the suspected occurrence of COVID-19 disease and the types of anti-epidemic measures and the manner in which they are implemented; and

(c) the extent of the data collected, the manner and time limits of their reporting.

(2) In addition, this Decree sets out in Annex 2 to that Decree additional data provided in the request for laboratory testing for the presence of SARS-CoV-2 virus or SARS-CoV-2 antigen sent by electronic means through the information systems of public health authorities.

§ 2

Efficacy

This Decree shall take effect on 1 May 2022.

Minister for Health:

Prof. MUDr. Válek, CSc., MBA, EBIR, v. r.

Příloha č. 1

Annex No 1 to Decree No. 101 / 2022 Coll.

Surveillance disease COVID-19

Basic characteristics and clinical definition of disease COVID-19

The origin of COVID-19 disease is the coronavirus SARS-CoV-2. This is an acute infectious disease, which may also have a asymptomatic course, in case of symptoms it is a disease with the predominant respiratory tract disorder, which is most commonly manifested by fever, dry irritant cough, cold, fatigue, malaise, shortness of breath, muscle and joint pain. Less common symptoms include diarrhoea and loss of appetite, feeling sick and vomiting, pain or scratches in the neck, in severe cases of pneumonia. Other symptoms of COVID-19 disease may result in loss of sense of smell and taste, headache, conjunctivitis, reduction of blood pressure, rapid breathing, rapid heart rate and excretion of insufficient urine. Exceptionally, skin rash or other organ involvement, such as myocardial infarction or other damage to the heart and blood vessels, acute renal impairment, neurological manifestations, hypercoagulation status with arterial and venous thrombosis and risk of pulmonary embolism may occur. Clinical signs at age may be inconspicuous, sometimes non-specific worsening of the health condition with apathy, confusion, dizziness or dehydration. Children may develop a multisystemic inflammatory response syndrome associated with COVID-19.

Classification of the disease

I. COVID-19 is classified as

1. possible, probable or confirmed case

A. a possible case meets the clinical criteria, which are the presence of at least one of the following: cough, fever, shortness of breath, sudden loss of smell or disorder or loss of taste,

B. probable case meets

i. clinical criteria with at least one of the following epidemiological links:

(a) epidemiological contact with a confirmed case of COVID-19 within 14 days prior to onset of symptoms of COVID-19,

(b) residence or work in a hospital providing bed-care or social services where the transmission of COVID-19 has been confirmed within 14 days prior to the onset of clinical symptoms; or

(c) stay in or return from areas with community disease transmission; or

ii. diagnostic imaging criteria which are radiological findings confirming lung damage consistent with COVID-19 disease;

C. a confirmed case which meets the laboratory criteria, which are:

(a) detection of SARS-CoV-2 nucleic acid in upper respiratory, lower respiratory, biopic material, corneal or other relevant clinical materials, in the event of death of bronchitis or lung swabs or, where appropriate, myocardium samples taken into a virological transport medium; or

(b) detection of SARS-CoV-2 antigen in upper respiratory tract biological material in cases meeting clinical criteria; or

(c) evidence of SARS-CoV-2 antigen in blood.

2. Suspected of having repeated infection ("suspected reinfection") COVID-19, which is defined as a newly detected positive result of the SARS-CoV-2 test using a polymerase chain reaction method with reverse transcription ("RT-PCR") or for the presence of SARS-CoV-2 antigen by rapid antigen test ("RAT") 60 days or more after

(a) the previous positive RT- PCR result;

(b) the previous positive result of the RAT; or

(c) prior positive serology, namely anti-spike SARS-CoV-2 IgG Ab in non-vaccinated against COVID-19 or anti-nucleocapside SARS-CoV-2 IgG Ab in individuals vaccinated against COVID-19.

3. Death due to COVID-19 is defined for surveillance purposes as death due to disease in a probable or confirmed case of COVID-19 disease, or sudden death with subsequently laboratory confirmed pathological findings, unless there is a clear alternative cause of death that cannot be related to COVID-19, such as trauma, cancer or severe immunodeficiency. There should be no period of complete recovery between disease and death.

Collection of data and the manner and timing of their reporting

1. The health service provider providing bed care shall send local reports of COVID-19 to the competent public health authority by electronic means through the register of the current health status of natural persons of public health authorities. The report shall be made without undue delay, at least once a day.

2. Reporting by the health service provider referred to in point 1 shall include:

(a) the name and, where applicable, the name and surname of the patient with disease COVID-19, his insured person's number or date of birth, unless the assigned number of the insured person, sex and nationality, and the code of the health insurance undertaking in which the patient with disease COVID-19 is insured;

(b) information on the admission of patients with COVID-19 to bed care;

(c) information on the care of a patient with COVID-19 disease;

i.

i. whose medical condition requires the use of respiratory support; or

iii. whose medical condition requires the use of extracorporal membrane oxygenation (ECMO);

(d) information that the condition of a patient with COVID-19 disease already receiving bed care,

i.

ii. newly requires the use of respiratory support; or

iii. newly requires the use of extracorporal membrane oxygenation (ECMO),

(e) information that the patient already provided in bed care,

i. is released from bed care; or

ii. died,

(f) the name of the provider, his ID number, serial number of the installation, contact e-mail and telephone number.

3. The provider of social services in a weekly stationary, a home for disabled persons, a home for seniors or a home with a special regime shall send a report on the disease COVID-19 to the competent public health authority electronically via the register of the current health status of natural persons of public health authorities. The report shall be made when a positive result of the laboratory examination of COVID-19 is found for persons receiving social services or for the staff of that provider. The report shall be made without undue delay, at least once a day.

4. The report of the social services provider referred to in point 3 shall include:

(a) the name and, where applicable, the name and surname of the person with disease COVID-19, the insured person's number and, where applicable, the date of birth, unless the person assigned the number of the insured person, his sex, nationality, and the code of the health insurance undertaking with which the person with proven disease COVID-19 is insured;

(b) whether a person with a proven disease is an employee of a provider or user of services,

(c) information on the date of implementation of the RT- PCR or RAT with a positive result and the condition of a person with a disease of COVID-19, including information on its death, indicating its date, if the death occurred within 30 days of the date of implementation of the RT- PCR or RAT with a positive result;

(d) the name of the provider, his ID, social service identifier, contact e-mail and telephone number.

5. A health service provider carrying out an examination for the presence of SARS-CoV-2 virus or SARS-CoV-2 virus antigen, hereinafter referred to as "the investigating provider ', shall report without delay to the public health authority the result of the examination electronically through the register of the actual health status of the natural persons of the public health authorities.

Epidemiological inquiry when suspected of occurrence of disease COVID-19

The public health authority, based on a risk assessment, carries out epidemiological investigations in an outbreak and on their return from abroad from areas where a new variant of SARS-CoV-2 virus has been identified, which is not widespread.

Types of anti-epidemic measures and method of implementation

Anti-epidemic measures in the occurrence of COVID-19 are in particular as follows:

1. the notification of the occurrence of the disease COVID-19 by the provider of health services to the public health authority referred to in Article 3 (1) and (2);

2. notification of the occurrence of the disease COVID-19 by the provider of social services to the public health authority pursuant to Article 3 (3) and (4);

3. reporting the result by the investigating public health authority provider referred to in Article 3 (5);

4. indications of the collection of biological material and the exposure of an electronic request for laboratory examination in case of suspected occurrence of a disease of COVID-19 by a health service provider or public health authority;

5. isolation; the isolation is ordered by the health service provider or the public health authority, where this is necessary to ensure the protection of public health, taking into account the outcome of the assessment of health risks, and is carried out in accordance with the instructions of the public health authority or health service provider at the designated site;

6. search for epidemiological contacts; persons in epidemiological contact with a positive person shall be informed by the public health authority of this fact by telephone, in writing to their e-mail address or in writing by means of a short text message,

7. quarantine measures; the quarantine measure shall be ordered by the health service provider or public health authority on the basis of the results of the risk assessment by persons in epidemiological contact with a positive person for the period strictly necessary to prevent the spread of the infection; in the case of medical supervision, the health service provider or the public health authority shall order the person in epidemiological contact with a positive person to undergo an X-PCR or RAT examination;

8. Regulation of the obligation to wear respiratory protection by an emergency measure of the public health authority;

9. Barrier isolation measures for treating patients with COVID-19 disease in health and social services facilities, including decontamination of surfaces and areas, use of adequate respiratory protection, mantle, gloves, washing and hand disinfection,

10. Protection measure ordering completion of the Access Form; The arrival form shall be completed by the person at the latest on entry into the territory of the Czech Republic from countries at risk of infection or from countries where new variants of the SARS-CoV-2 virus are not widespread (hereinafter referred to as "risk country '), electronically; according to the list of countries published on the website of the public health authority according to the current epidemiological situation as prevention of introduction and further spread of the disease from abroad; the access form contains:

(a) the name and, where appropriate, the name and surname of the person;

(b) the person's birth number and, where applicable, the date of birth of the person, if the person has no birth number,

(c) contact details of the person, in particular e-mail and telephone number,

(d) nationality,

(e) passport or ID number;

(f) country visited 14 days before arrival in the Czech Republic,

(g) date of arrival in the Czech Republic,

(h) the type of means of transport;

(i) the place of residence in the Czech Republic;

(j) an indication of the members of the family who are jointly travelling together if they are under 18 years of age and do not complete a separate form, to the extent of the name and, where appropriate, the name and surname of the person, the date of birth;

k) information about contact with person with confirmed disease COVID-19 in the last 14 days prior to arrival in the Czech Republic,

11. the obligation to test for the presence of SARS-CoV-2 virus or SARS-CoV-2 antigen via RT-PCR or RAT to persons on arrival or arrival from risk countries; the public health protection authority lays down this obligation for persons according to the current epidemiological situation;

12. timely information on the outcome of the laboratory examination of the persons under investigation; the investigating provider carrying out the SARS-CoV-2 virus test shall communicate the result of the laboratory examination to the person examined by electronic means without undue delay, by means of a short text message sent by a public mobile telephone network or data message sent by electronic mail; the testing provider carrying out the SARS-CoV-2 antigen test shall communicate the result of the examination to the person immediately after the result of the test, in oral form at the site of the examination.

Příloha č. 2

Annex No 2 to Decree No. 101 / 2022 Coll.

Data reported in the request for laboratory tests

1. The application for laboratory testing for the presence of SARS-CoV-2 virus or SARS-CoV-2 antigen in addition to the data provided for by the law also contains:

(a) unique numeric identifier of the request;

(b) the natural number of the person under investigation and, where appropriate, the date of birth of the person under investigation, if the person has no birth number,

(c) contact details of the person under investigation, in particular e-mail or telephone number,

(d) the nationality of the person under investigation;

(e) the identification number and address of the health service provider that indicated the examination;

(f) the workplace identification number (IČP) indicated by the examination;

(g) the name, if any, and surname, e-mail and telephone number of the doctor requesting the examination of the biological material;

(h) the code number of the health insurance undertaking to which the person under investigation is insured;

(i) the type of material, date and hour of collection;

(j) the date of the first symptoms and symptoms of infection in the person under investigation;

(k) preferred sampling point;

(l) reason for indication,

(m) the clinical diagnosis of the subject;

(n) the type of examination required; and

(o) the date of issue of the application.

2. In the case of the issue of a request for testing in an outbreak or screening test, in addition to the data referred to in paragraph 1, the employer's identification number of the person under investigation and the identification number of the school or school establishment in which he or she is trained or provided with school services shall be indicated.

Citation	Decree No. 101 / 2022 Coll., on the epidemiological vigilance system for COVID-19 disease
Regulation Type	Order
Author	-
Collection	Code of Laws

Date of Promulgation	29.04.2022
Effective from	01.05.2022
Effective until	-
Status	Valid

Decree No. 101 / 2022 Coll.

Decree on the epidemiological vigilance system for COVID-19

Contents

§ 1

§ 2

Příloha č. 1

Příloha č. 2

Contents

Comments 0

Regulation Information

Public Contracts 4

Partner Websites

Favorites

Browsing History